Journal of cancer science and clinical therapeutics最新文献

{"title":"A Phase I dose escalation trial using Intensity-Modulated Radiotherapy with simultaneous integrated boost in Pelvic Chemoradiotherapy for Metastatic Rectal Cancer","authors":"T. Lizée, V. Seegers, J. Blanchecotte, E. Rio, O. Capitain, V. Guérin-Meyer, F. Legouté, D. Autret, M. Mahé, A. Paumier","doi":"10.21203/rs.3.rs-127929/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-127929/v1","url":null,"abstract":"\u0000 BackgroundIn unresectable metastatic rectal cancers, the surgery of the primitive tumor remains highly debated. Chemoradiotherapy (CRT) of the primitive could allow sufficient local control in order to avoid major and sometimes mutilating surgery. Dose escalation during CRT could increase this local control. The aim of this study was to evaluate the feasibility and tolerance of a CRT with radiation dose escalation delivered in intensity modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB), in metastatic low and middle rectal cancers.MethodsThis multicenter phase I study included six patients treated for unresectable synchronous metastatic low and middle rectal adenocarcinoma in two dose levels. Radiotherapy was delivered using IMRT with SIB. The dose escalation was 52.5 Gy (level 1) and 56.25 Gy (level 2) in the primary tumor, in 25 fractions of 2.1 Gy and 2.25 Gy, respectively. High-risk clinical target volume (CTV) and low-risk CTV received respectively 50 Gy and 45 Gy in 25 fractions in the two levels. Concomitant chemotherapy was oral capecitabine and CRT was performed after four cycles of mFOLOX6 chemotherapy. The dose-limiting toxicity (DLT) was defined by a toxicity requiring the interruption of radiotherapy for more than five consecutive fractions.ResultsAll six patients received the full course of treatment at scheduled doses. No patients had acute toxicity requiring interruption of radiotherapy therefore no DLT has been reported. No patients had acute toxicity ≥ 3. Concerning late toxicity, three patients experienced grade 3. After CRT, four patients had a partial response and one patient had a complete clinical response. Two patients were considered in local progression at 9.4 months and 20.4 months of inclusion.ConclusionsDose escalation at 56.25 Gy in the tumor lesion was possible with good acute tolerance. It needs to be evaluated in a larger study. It could allow sufficient local control in order to avoid mutilating surgery in these metastatic patients.Trial registrationNCT03634202. Registered 16 August 2018 – retrospectively registered, https://www.clinicaltrials.gov/ct2/show/NCT03634202","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42453291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of circulating VEGF as a predictive biomarker of peritoneal carcinomatosis in gastric cancer","authors":"","doi":"10.36879/jcst.20.000121","DOIUrl":"https://doi.org/10.36879/jcst.20.000121","url":null,"abstract":"Introduction: Early diagnosis of peritoneal carcinomatosis is difficult in patients with gastric cancer who are at high risk of developing\u0000peritoneal metastases. The measurement of serum Vascular Endothelial Growth Factor (VEGF) has proven to be a useful prognostic\u0000factor in gastric cancer, but it also could be a predictive factor for peritoneal metastases since the VEGF signalling pathway is directly\u0000involved in the development of peritoneal metastases.\u0000Methods: This is a retrospective study from 2005 to 2017. We reviewed the peritoneal recurrence pattern of a cohort of 59 gastric\u0000cancer patients in whom serum VEGF was measured before surgery and after completion of adjuvant treatment\u0000Results: Preoperative serum VEGF (pre-VEGF) level was identified as an independent prognostic factor for developing peritoneal\u0000metastases. The optimal cut-off value of pre-VEGF levels was 507 pg/mL, which presented a sensitivity of 66 % and a specificity of\u000078% to predict the development of peritoneal metastases. Patients with high pre-VEGF levels (>507 pg/mL) were at greater risk of\u0000developing peritoneal metastases than patients with low pre-VEGF levels (<507 pg/mL) (p=0.023).\u0000Conclusions: VEGF plays a crucial role in the development of peritoneal metastases, and serum VEGF meets the requirements of a\u0000potential predictive marker for peritoneal carcinomatosis. Therefore, the measurement of serum VEGF levels could be useful during\u0000the follow-up of patients with advanced gastric cancer.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"91 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84402989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis analysis of patients with resectable T4 colorectal cancer","authors":"Wei Chen, Xiao-ping Tan, Junwen Ye, Yan Zhang, Jing-lin Liang, Mei Huang","doi":"10.21203/rs.3.rs-37853/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-37853/v1","url":null,"abstract":"\u0000 Objective: To observe the factors related to survival and prognosis of patients with resectable stage T4 colorectal cancer. Methods : 148 patients with resectable stage T4 colorectal cancer who underwent surgery in the first Affiliated Hospital of Sun Yat-sen University between August, 1994 and December, 2005 were retrospectively analyzed. Univariate and multivariate analyses of associations between clinicopathological variables and survival were analyzed using the Cox regression model. Results: At the end of December of 2010 or death, the 5-year and 10 years OS rates were 49.0% and 32.2% respectively, the median OS was 25 months. The disease free survival rates (DFS) at 5 and 10 years were 44.2% and 30.3% respectively. In univariate analysis, patients with postoperative pathology lymph node metastasis was associated with the prognosis of patients with OS (all P< 0.01), postoperative adjuvant therapy failed to improve OS and DFS (P>0.05). Postoperative pathology lymph node metastasis was associated with DFS too (all P< 0.01). In multivariate analysis, postoperative pathology lymph node metastasis was independent factor affected OS and DFS in colorectal cancer patients. Conclusion: Postoperative prognosis of T4 colorectal cancer patients is poor, postoperative pathology lymph node positive was an independent factor affect OS and DFS.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42894791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PD-L1 regulation in colorectal cancer and role of DNA damage induced by chemotherapies","authors":"","doi":"10.36879/jcst.20.000120","DOIUrl":"https://doi.org/10.36879/jcst.20.000120","url":null,"abstract":"For patients with metastatic colorectal cancer (CRC), first-line therapy is based on chemotherapeutic agents, such as oxaliplatin,\u00005-fluorouracil and irinotecan. These drugs increase the overall survival, but resistance to therapy appears in almost 90% of patients,\u0000and the 5-year survival rate for patients with metastatic CRC is only about 12%.\u0000During the last few years, immune checkpoints blockade therapies have been developed and show good response in different cancers,\u0000including CRC with microsatellite instability (MSI). In this CRC subtype, the response rate to anti-PD-(L)1 antibodies is high thanks to\u0000the presence of neoantigens and tumor-infiltrating lymphocytes that are associated with the anti-tumor immune response. Nivolumab\u0000and pembrolizumab, two anti-PD-1 antibodies, have been approved for CRC MSI treatment. Moreover, it has been shown that the\u0000combination of chemotherapy and anti-PD-(L)1 molecules may convert cold tumors into hot tumors in which the immune system and\u0000T-cell infiltration are activated. In addition, recent studies found that DNA damage induces PD-L1 expression. ATM, ATR, DNA-PKcs\u0000and Chk1 are key sensors of the DNA damage response that regulate PD-L1 expression.\u0000This review summarizes the current knowledge on PD-L1 regulation at the genetic, epigenetic, transcriptional and translational\u0000levels. It also describes PD-L1 activation in response to chemotherapy and DNA damage. Then, it summarizes the current clinical\u0000trials that assess anti-PD-(L)1 therapies in combination with kinase inhibitors or chemotherapeutic agents in CRC.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84042792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review on moderated-t methods for differential expression detection","authors":"","doi":"10.36879/jcst.20.000119","DOIUrl":"https://doi.org/10.36879/jcst.20.000119","url":null,"abstract":"With the advancement of high-throughput technology, identifying differential expression has become an essential task in multiple domains of\u0000biomedical research, such as transcriptome, proteome, metabolome. A wide variety of computational methods and statistical approaches were\u0000developed for detecting differential expression. Most of these methods were applicable to modeling expression level of the entire set of features\u0000simultaneously. In this article, we provide a review emphasizing on moderated-t methods published in last two decades. We compared similarities\u0000and differences between them, and also discussed their limitations in applications.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91044270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capillary leak syndrome (CLS) from rituximab therapy of lymphoma","authors":"","doi":"10.36879/jcst.20.000118","DOIUrl":"https://doi.org/10.36879/jcst.20.000118","url":null,"abstract":"Capillary Leak Syndome (CLS) is characterized by plasma extravasation into the interstitium with resultant hypotension, anasarca, hemoconcentration,\u0000and hypoalbuminemia in the absence of albuminuria. Initially reported in Clarkson’s disease (systemic capillary leak syndrome, SCLS), CLS has\u0000been observed in multiple disease settings, the most common being sepsis. In Oncology, CLS has been reported more often as a complication from\u0000therapy, and less often from malignancy. In this case study, we documented clinical manifestation, laboratory features and radiological findings of\u0000CLS from rituximab therapy when employed in combination with a multi-agent chemotherapy regimen (EPOCH-R). Differentiating drug-induced\u0000CLS from sepsis, which presents with the same clinical features, is important in avoiding further exposure to rituximab, which could be fatal to the\u0000patient.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"181 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77497686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Australia mortality from melanoma is decreasing but increasing for nonmelanoma skin cancer","authors":"","doi":"10.36879/jcst.20.000117","DOIUrl":"https://doi.org/10.36879/jcst.20.000117","url":null,"abstract":"Mortality from melanoma is decreasing in Australia since 2013. Deaths from non-melanoma skin cancer are increasing.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84979408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Summary and case observation of tumour treating fields therapy for glioblastoma","authors":"L. Zeng, Y-H Liu, X. Wang, Y. Luo, L. Xie, P. Li, L. Bai","doi":"10.36879/jcst.20.000116","DOIUrl":"https://doi.org/10.36879/jcst.20.000116","url":null,"abstract":"L Zeng1, X-Q Xie2, D-B Wu3, Y-Z Liu4, J-B Kang5, B-L Qu6, P Ai1, Q Mao9, Y-H Liu9, X Wang9, Y Luo1, L Xie1, P Li1, L Bai1, F Wang1*, X.-F Li7*, J-J Wang8* and W-M Li10 1Department of Medical Oncology, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan, P.R. China 2Department of Critical Care Medicine, West China Hospital, Sichuan University, Sichuan, P.R. China 3Cancer Hospital, Ansteel Group Hospital, Anshan, Liao Ning, P.R. China 4Department of Radiotherapy, Beijing Hospital, Beijing, P.R. China 5Department of Radiotherapy, The Sixth Medical Center of PLA General Hospital, Beijing, P.R. China 6Department of Radiotherapy, Chinese PLA General Hospital, Beijing, P.R. China 7Department of Radiotherapy, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, P.R. China 8Department of Radiation Oncology Cancer Center, Peking University 3rd Hospital, P.R. China 9Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China 10Precision medicine center, West China Hospital, West China Medical School, Sichuan University, Sichuan, P.R. China","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"91 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81555761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder-sparing trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: A systematic review and meta-analysis of comparative studies","authors":"","doi":"10.36879/jcst.20.000115","DOIUrl":"https://doi.org/10.36879/jcst.20.000115","url":null,"abstract":"Objective: To compare oncologic outcomes between patients with muscle-invasive bladder cancer who were treated with radical cystectomy (RC) or\u0000trimodal therapy (TMT).\u0000Materials and Methods: The primary sources were the PubMed, Embase, and Cochrane Library electronic databases. Studies published between\u0000June 1990 and July 2017 that evaluated combination bladder-sparing surgery for a bladder tumour with radiotherapy (RT) and chemotherapy\u0000compared with RC surgery alone for MIBC were included. Published data were extracted and used to calculate the 5-year overall survival rates. The\u0000secondary efficacy endpoints were disease-free survival and local and distant recurrence.\u0000Results: Nine studies incorporating 15,160 cases were included in the final analysis. Pooled data from 8 studies that assessed overall survival rates\u0000for 15,089 patients showed no significant differences in this metric between the TMT and RC groups (HR: 1.27; 95% CI, 0.98-1.63; P=0.066). No\u0000significant differences were found between TMT and RC in the subgroup analyses according to the lymph node stage (Nx), age and physiclal status\u0000(PS) stage, but differences were found for patients with node-negative disease (HR: 1.36; 95% CI, 1.02-1.81; P=0.036). Disease-free survival and\u0000local and distant recurrence did not differ significantly between the techniques.\u0000Conclusion: RC seems to be suitable for node-negative disease patients. TMT yielded survival outcomes similar to those of patients who underwent\u0000RC. Given the inherent limitations of the included studies, future well-designed RCTs are needed to confirm and update the findings of this analysis.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"497 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78261194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories of hospitalization in three groups of patients with incurable gastric cancer identified by hierarchical clustering: A retrospecitve analysis","authors":"Y. Murakawa, M. Sakayori, Kazunori Otsuka","doi":"10.21203/rs.2.20848/v1","DOIUrl":"https://doi.org/10.21203/rs.2.20848/v1","url":null,"abstract":"Purpose: The therapeutic goal for advanced solid malignancies is not to achieve cure but to prolong survival and maintain quality of life (QOL). To date, no study has reported the trajectory of the QOL throughout the clinical course of a patient with advanced malignancy. As hospitalization is considered a predictor of QOL, we retrospectively analyzed the trajectory of hospitalization in patients with incurable gastric cancer throughout the clinical course. Methods: The data of 85 patients with incurable gastric cancer were collected, including age, sex, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), treatment, histology, sites of metastases at first consultation, planned and unplanned hospitalization throughout the clinical course , and overall survival (OS). We ranked the patients by OS and hospitalization using a hierarchical clustering analysis. Results: Three clusters were identified corresponding to short, intermediate, and long OS/hospitalization (Clusters 1, 2, and 3, respectively). Patients in Cluster 3 were more likely to have an ECOG PS of 0–2 and receive palliative chemotherapy than the other clusters. No other differences in histology, age, sex, and or extra-peritoneal metastasis sites were observed between the three groups. In Cluster 3, planned hospitalization accumulated gradually during the early clinical phase, while unplanned hospitalization accumulated rapidly in later phases. Conclusions: No specific characteristics were associated with short, intermediate, and long OS/hospitalization. Patients in the long OS/hospitalization group exhibited a rapid accumulation of unplanned hospitalization during the latter clinical course. Further research is needed to identify specific predictors of and measures to avoid a long OS/hospitalization.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45565932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}